- Save article
NewsSanofi Pension Scheme signs £1.4bn buy-in with Legal & General
All members of the scheme are now insured via buy-ins with Legal & General
- Save article
NewsSanofi UK pension scheme agrees £760m buy-in with L&G
First pension risk transfer with the insurer after being a long-term asset management client
- Save articleNews
Germany added to Sanofi pension fund in Belgium cross-border first
‘This will open doors for other multinational corporations,’ says Aon
White papersProducing in Europe for Europe: why reindustrialisation is the next big real estate play
We explore Europe’s focus on resilience, highlighting prospects in securing supply chains and spurring innovation.
- Save article
NewsFondaereo’s cross-border project could shake up landscape as EU reviews IORP II
IORP II directive has ‘complicated the regulatory landscape, says CBBA’s Francesco Briganti
White papersUncovering the qualities that set compounders apart
Compounder companies (“compounders”) are those with highly visible and long-duration growth. Lindy’s Law explains an anti-ageing process for such companies — the longer they exist, the stronger they become to survive well into the future. This enables many to become industry leaders and dominant global players. We refer to these types of venerable companies as “marathon runners”. They form the bedrock of the returns we generate for our clients. It’s not just their age that sets these companies apart. It’s the combination of unique corporate culture and resilience that keeps them growing in good and bad times.
White papersA closer look at European equities
Interview with Arun Singhal, Global Head of Product Management at STOXX.
- Save articleNews
Cross-border IORPs down to 33 post-Brexit, says EIOPA in new report
Supervisory authority publishes first in series of annual reports dedicated to cross-border pension funds
- Save article
Special ReportBelgium: First-pillar reform caps highest pensions
Federal government manages to work out a first-pillar agreement before the parliamentary recess
- Save article
NewsWellcome says 34.5% returns will reinforce new strategy and raised ambitions
The charity said the ‘exceptional’ performance for 2020/21 came largely from its private assets
- Save article
NewsEIOPA names members of new pensions stakeholder group
PensionsEurope’s Leppälä and APG’s Steenbeek among returning, new IORP representatives
- Save article
Asset Class ReportsFixed Income – European investment grade: No sign of end for negative yields
Negative interest rates look set for a lengthy run in Europe, raising concerns about the long-term effects
- Save article
Asset Class ReportsInnovation is key for pharma
Europe’s pharmaceuticals sector must be innovative to stay ahead of global rivals
- Save articleNews
IPE Views: Can Europe win the dengue race?
Joseph Mariathasan explores the impact of – and possible solution to – the growing dengue epidemic
- Save articleAsset Class Reports
European pharma under threat
Pharmaceuticals have long been the foundation of Europe’s industrial base. Now the sector must fight back against the threat of US biotech companies
- Save articleSpecial Report
SDG reporting: Beyond SDG-washing
Only thorough processes and due diligence can make sense of the welter of claims and frameworks by companies using the SDGs as a reporting tool
- Save articleSpecial Report
Top 400 Asset Managers: Outcomes revolution in investment management and pharmaceuticals
Mitesh Sheth outlines what investment managers can learn from the transformation taking place in the pharmaceutical industry
Asset Manager NewsPharmaceutical companies in a golden age for drug discovery
As new technologies such as genomics spur development of innovative drugs, European pharmaceuticals companies stand out as high-quality, defensive growth stocks
- Save articleNews
Joseph Mariathasan: Europe’s pharmaceutical and biotech industries
Europe’s pharmaceutical sector must find a way to emulate US biotech, Joseph Mariathasan writes
- Save article
NewsDrug companies suffer from lack of sustainability, says oekom
Pharmaceutical companies 'react rather than act', according to ratings agency.
Search results
Copyright © 1997–2025 IPE International Publishers Limited, Registered in England, Reg No. 3233596, VAT No. 685 1784 92. Registered Office: 1 Kentish Buildings, 125 Borough High Street, London SE1 1NP
Site powered by Webvision Cloud